1. Home
  2. IRD vs PXS Comparison

IRD vs PXS Comparison

Compare IRD & PXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • PXS
  • Stock Information
  • Founded
  • IRD 2018
  • PXS 2015
  • Country
  • IRD United States
  • PXS Greece
  • Employees
  • IRD N/A
  • PXS N/A
  • Industry
  • IRD
  • PXS Marine Transportation
  • Sector
  • IRD
  • PXS Consumer Discretionary
  • Exchange
  • IRD NYSE
  • PXS Nasdaq
  • Market Cap
  • IRD 35.7M
  • PXS 38.2M
  • IPO Year
  • IRD N/A
  • PXS N/A
  • Fundamental
  • Price
  • IRD $0.93
  • PXS $3.28
  • Analyst Decision
  • IRD Strong Buy
  • PXS Strong Buy
  • Analyst Count
  • IRD 1
  • PXS 1
  • Target Price
  • IRD $8.00
  • PXS $10.00
  • AVG Volume (30 Days)
  • IRD 141.6K
  • PXS 14.6K
  • Earning Date
  • IRD 03-25-2025
  • PXS 03-21-2025
  • Dividend Yield
  • IRD N/A
  • PXS N/A
  • EPS Growth
  • IRD N/A
  • PXS 63.38
  • EPS
  • IRD N/A
  • PXS 2.85
  • Revenue
  • IRD $8,381,000.00
  • PXS $52,756,000.00
  • Revenue This Year
  • IRD N/A
  • PXS $5.52
  • Revenue Next Year
  • IRD $29.37
  • PXS N/A
  • P/E Ratio
  • IRD N/A
  • PXS $1.16
  • Revenue Growth
  • IRD N/A
  • PXS 4.27
  • 52 Week Low
  • IRD $0.81
  • PXS $3.24
  • 52 Week High
  • IRD $2.34
  • PXS $5.53
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • PXS 26.96
  • Support Level
  • IRD N/A
  • PXS $3.27
  • Resistance Level
  • IRD N/A
  • PXS $3.53
  • Average True Range (ATR)
  • IRD 0.00
  • PXS 0.09
  • MACD
  • IRD 0.00
  • PXS -0.02
  • Stochastic Oscillator
  • IRD 0.00
  • PXS 8.83

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About PXS Pyxis Tankers Inc.

Pyxis Tankers Inc is an international maritime transportation company that focuses on the product tanker sector. It owns a fleet that comprises double-hull product tankers employed under a mix of short- and medium-term time charters and spot charters. The fleet owned by the company includes Pyxis Epsilon, Pyxis Theta, Pyxis Malou, Northsea Alpha, and Northsea Beta. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, fuel oil, and other liquid bulk items, such as vegetable oils and organic chemicals.

Share on Social Networks: